Cemiplimab’s mechanism of action

Cemiplimab (Cemiplimab) is an immune checkpoint inhibitor whose main function is to treat cancer by regulating the immune system. Its mechanism of action involves key molecular and cellular interactions in the immune system, helping to enhance the immune system's attack on cancer cells. Here is how cimepilimab works:

1.PD-1/PD-L1Inhibition: Cimepilimab targets the PD-1 (programmed death -1) receptor. PD-1 is an immune checkpoint receptor that exists on the surface of T lymphocytes and is used to maintain the balance of the immune system. When the PD-1 receptor binds to its ligand PD-L1 (programmed death ligand 1), it inhibits the activity of T cells, thereby weakening the immune response. Cancer cells use PD-L1 to avoid being attacked by the immune system.

2.Immune enhancement: Cimepilimab relieves the inhibition of T cells by blocking the combination of PD-1 and PD-L1. This means that activated TT cells can more effectively identify, attack and eliminate cancer cells. This way, the immune system can be more robust against cancer.

3.Enhance cytotoxicity: In addition to enhancing the activity of T cells, cimepilimab may also prompt other immune cells, such as natural killer cells (NK cells) and antigen-presenting cells, to work better together to enhance the killing of cancer cells.

4.Anti-tumor immune memory: Treatment with cimipilimab also helps form immune memory against cancer cells. This means that even after treatment ends, the immune system can remain vigilant against cancer cells to prevent the cancer from returning.

Cimeplimab is not currently available in China, so patients cannot purchase it domestically and need to purchase cimeplimab through overseas channels. There are only cimepri monoclonal original drugs abroad, mainly European and American versions. The European version is about 40,000, and the American version is about 100,000. Both are original drugs, and their drug ingredients and efficacy are the same.